Nobel Prize-winning tagging system used to map a new class of drug targets in cancer and immunology
Researchers at the Francis Crick Institute and Imperial College London have used ‘click chemistry’, which won scientists the 2022 Nobel Prize in Chemistry, to map the role of a group of enzymes that could be key for developing new medicines in cancer and immunology.
Many proteins known to be linked to disease can’t be targeted directly as they are too floppy or too smooth to provide a foothold for a drug to bind. Instead, researchers need to target them indirectly via processes that modify them.
A type of modification called palmitoylation involves attaching a fat molecule (known as a lipid), so the protein can bind to the fatty membranes which envelop the contents of the cell, allowing it to take on a particular function.
Enzymes called ZDHHCs are responsible for directing palmitoylation to specific proteins, so offer a new way to target proteins indirectly in diseases. However, humans have 23 different ZDHHCs, and understanding which proteins each one modifies, and therefore also which might be best targeted in disease, has been very challenging.
Through research published today in Nature Biotechnology the team used a method called ‘bump and hole’, which involves putting a ‘hole’ into a ZDHHC enzyme and a ‘bump’ into the lipid, so that they fit together. They then combined this technology with click chemistry so that any protein receiving the ‘bumped’ lipid from this ZDHHC will be tagged.
This method allows identification of the specific proteins one ZDHHC modifies for the first time. Proteins which are related to disease can, in future, be targeted indirectly by inhibiting the associated ZDHHC.
To progress the research into drug discovery, the researchers have also screened a very large library of compounds to find effective ZDHHC inhibitors.
Ed Tate, Group Leader of the Chemical Biology and Therapeutic Discovery Satellite Laboratory at the Crick and the GSK Chair in Chemical Biology at Imperial College London, said: “Using this precise tagging system to identify which enzymes target specific proteins will allow us to understand what happens if we block these enzymes.
“This new approach building on Nobel Prize-winning technology will be fundamental for furthering drug development, allowing us to develop medicines which indirectly target currently ‘undruggable’ proteins. It could be used to find new drugs for cancer and immune disorders, but also to fight infectious diseases like malaria. We’re just at the beginning of this exciting journey, but we expect that drugs developed based on this method could be in clinical trials within five years.”
Tony Ocasio, former Senior Laboratory Research Scientist at the Crick, and now Senior Screening Platform Scientist at Econic Biosciences, said: “This multi-collaborative and interdisciplinary project marries two disparate fields within the chemical and biological sciences, highlighting what we can achieve when scientists work together. Being able to apply a bump-hole strategy to the ZDHHCs and pairing this with chemical proteomics is truly a game changer. My hope is that this technology reinvigorates the lipid biology field by providing tools to link specific substrate palmitoylation to disease, and creating drug discovery programmes aimed at developing therapies around management of these ZDHHC targets.”
Paul Mercer, Head of Collaboration at the Crick, said: "This ground-breaking work exemplifies the Crick’s vison of making discoveries without boundaries, adding a powerful new layer to the unique suite of ZDHHC technologies developed by Ed Tate’s group at the Crick and Imperial College London. The platform unlocks the exciting prospect of developing novel drugs against an entirely new target class, with potential in a range of high-value disease areas which the team are actively pursuing."
Funded by Cancer Research UK, this was a coordinated effort across multiple teams at the Crick and Imperial College London. Ed and first author Tony Ocasio worked with Julian Downward, group leader of the Oncogene Biology Laboratory; James Macrae, head of the Metabolomics facility; and the Chemical Biology team.
Reference: Ocasio, C. et al. (2024). A palmitoyl transferase chemical-genetic system to map ZDHHC-specific S-acylation. Nature Biotechnology. 10.1038/s41587-023-02030-0.
An earlier version of this article was first reported on bioRxiv: https://www.biorxiv.org/content/10.1101/2023.04.18.537386v1
The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the fundamental biology underlying health and disease. Its work is helping to understand why disease develops and to translate discoveries into new ways to prevent, diagnose and treat illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases.
An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King’s College London.
The Crick was formed in 2015, and in 2016 it moved into a brand new state-of-the-art building in central London which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under a single roof in Europe.
About Imperial College London
Imperial College London is a global top ten university with a world-class reputation. Imperial’s 22,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering and business.
Imperial ranks sixth in the 2024 QS World University Rankings and eighth in the 2024 Times Higher Education World University Rankings. The 2021 Research Excellence Framework (REF) found that it has a greater proportion of world-leading research than any other UK university. It also received a Gold Award in the 2023 Teaching Excellence Framework (TEF). Imperial was named University of the Year in the Daily Mail University Guide 2024, University of the Year for Graduate Employment in The Times and Sunday Times Good University Guide 2024, and awarded a Queen’s Anniversary Prize for its COVID-19 response.
About Cancer Research UK
- Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research, influence and information.
- Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 50 years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK wants to accelerate progress and see 3 in 4 people surviving their cancer by 2034.
- Cancer Research UK supports research into the prevention and treatment of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK is working towards a world where people can live longer, better lives, free from the fear of cancer.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook
